tetano
Editor, Senior Moderator
Cell Host Microbe
. 2021 Dec 3;S1931-3128(21)00569-2.
doi: 10.1016/j.chom.2021.12.004. Online ahead of print.
Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses
Alexandra Tauzin[SUP] 1 [/SUP], Shang Yu Gong[SUP] 2 [/SUP], Guillaume Beaudoin-Bussières[SUP] 1 [/SUP], Dani Vézina[SUP] 3 [/SUP], Romain Gasser[SUP] 1 [/SUP], Lauriane Nault[SUP] 1 [/SUP], Lorie Marchitto[SUP] 1 [/SUP], Mehdi Benlarbi[SUP] 3 [/SUP], Debashree Chatterjee[SUP] 3 [/SUP], Manon Nayrac[SUP] 1 [/SUP], Annemarie Laumaea[SUP] 1 [/SUP], Jérémie Prévost[SUP] 1 [/SUP], Marianne Boutin[SUP] 1 [/SUP], Gérémy Sannier[SUP] 1 [/SUP], Alexandre Nicolas[SUP] 1 [/SUP], Catherine Bourassa[SUP] 3 [/SUP], Gabrielle Gendron-Lepage[SUP] 3 [/SUP], Halima Medjahed[SUP] 3 [/SUP], Guillaume Goyette[SUP] 3 [/SUP], Yuxia Bo[SUP] 4 [/SUP], Josée Perreault[SUP] 5 [/SUP], Laurie Gokool[SUP] 3 [/SUP], Chantal Morrisseau[SUP] 3 [/SUP], Pascale Arlotto[SUP] 3 [/SUP], Renée Bazin[SUP] 5 [/SUP], Mathieu Dubé[SUP] 3 [/SUP], Gaston De Serres[SUP] 6 [/SUP], Nicholas Brousseau[SUP] 6 [/SUP], Jonathan Richard[SUP] 1 [/SUP], Roberta Rovito[SUP] 7 [/SUP], Marceline Côté[SUP] 4 [/SUP], Cécile Tremblay[SUP] 1 [/SUP], Giulia C Marchetti[SUP] 7 [/SUP], Ralf Duerr[SUP] 8 [/SUP], Valérie Martel-Laferrière[SUP] 9 [/SUP], Daniel E Kaufmann[SUP] 10 [/SUP], Andrés Finzi[SUP] 11 [/SUP]
Affiliations
Abstract
The standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses administered three weeks apart. However, some public health authorities spaced these doses, raising questions about efficacy. We analyzed longitudinal humoral responses against the D614G strain and variants of concern for SARS-CoV-2 in a cohort of SARS-CoV-2-naive and previously infected individuals who received the BNT162b2 mRNA vaccine with sixteen weeks between doses. While administering a second dose to previously infected individuals did not significantly improve humoral responses, these responses significantly increased in naive individuals after a 16-week spaced second dose, achieving similar levels as in previously infected individuals. Comparing these responses to those elicited in individuals receiving a short (4-week) dose interval showed that a 16-week interval induced more robust responses among naive vaccinees. These findings suggest that a longer interval between vaccine doses does not compromise efficacy and may allow greater flexibility in vaccine administration.
Keywords: ADCC; COVID-19; Coronavirus; SARS-CoV-2; Spike glycoproteins; delayed mRNA vaccine regimen; humoral responses; neutralization; variants of concern; variants of interest.
. 2021 Dec 3;S1931-3128(21)00569-2.
doi: 10.1016/j.chom.2021.12.004. Online ahead of print.
Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses
Alexandra Tauzin[SUP] 1 [/SUP], Shang Yu Gong[SUP] 2 [/SUP], Guillaume Beaudoin-Bussières[SUP] 1 [/SUP], Dani Vézina[SUP] 3 [/SUP], Romain Gasser[SUP] 1 [/SUP], Lauriane Nault[SUP] 1 [/SUP], Lorie Marchitto[SUP] 1 [/SUP], Mehdi Benlarbi[SUP] 3 [/SUP], Debashree Chatterjee[SUP] 3 [/SUP], Manon Nayrac[SUP] 1 [/SUP], Annemarie Laumaea[SUP] 1 [/SUP], Jérémie Prévost[SUP] 1 [/SUP], Marianne Boutin[SUP] 1 [/SUP], Gérémy Sannier[SUP] 1 [/SUP], Alexandre Nicolas[SUP] 1 [/SUP], Catherine Bourassa[SUP] 3 [/SUP], Gabrielle Gendron-Lepage[SUP] 3 [/SUP], Halima Medjahed[SUP] 3 [/SUP], Guillaume Goyette[SUP] 3 [/SUP], Yuxia Bo[SUP] 4 [/SUP], Josée Perreault[SUP] 5 [/SUP], Laurie Gokool[SUP] 3 [/SUP], Chantal Morrisseau[SUP] 3 [/SUP], Pascale Arlotto[SUP] 3 [/SUP], Renée Bazin[SUP] 5 [/SUP], Mathieu Dubé[SUP] 3 [/SUP], Gaston De Serres[SUP] 6 [/SUP], Nicholas Brousseau[SUP] 6 [/SUP], Jonathan Richard[SUP] 1 [/SUP], Roberta Rovito[SUP] 7 [/SUP], Marceline Côté[SUP] 4 [/SUP], Cécile Tremblay[SUP] 1 [/SUP], Giulia C Marchetti[SUP] 7 [/SUP], Ralf Duerr[SUP] 8 [/SUP], Valérie Martel-Laferrière[SUP] 9 [/SUP], Daniel E Kaufmann[SUP] 10 [/SUP], Andrés Finzi[SUP] 11 [/SUP]
Affiliations
- PMID: 34953513
- DOI: 10.1016/j.chom.2021.12.004
Abstract
The standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses administered three weeks apart. However, some public health authorities spaced these doses, raising questions about efficacy. We analyzed longitudinal humoral responses against the D614G strain and variants of concern for SARS-CoV-2 in a cohort of SARS-CoV-2-naive and previously infected individuals who received the BNT162b2 mRNA vaccine with sixteen weeks between doses. While administering a second dose to previously infected individuals did not significantly improve humoral responses, these responses significantly increased in naive individuals after a 16-week spaced second dose, achieving similar levels as in previously infected individuals. Comparing these responses to those elicited in individuals receiving a short (4-week) dose interval showed that a 16-week interval induced more robust responses among naive vaccinees. These findings suggest that a longer interval between vaccine doses does not compromise efficacy and may allow greater flexibility in vaccine administration.
Keywords: ADCC; COVID-19; Coronavirus; SARS-CoV-2; Spike glycoproteins; delayed mRNA vaccine regimen; humoral responses; neutralization; variants of concern; variants of interest.